|
D. Eekers; E. Roelofs; M. Cubillos-Mesias; C. Niël; R.Jan Smeenk; A. Hoeben; A.W.H. Minken; J.H.A.M. Kaanders; P. Lambin; E.G.C. Troost |
Data from: Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial |
2018 |
|
J. van Timmeren; R.T.H. Leijenaar; W. van Elmpt; B. Reymen; C. Oberije; R. Monshouwer; J. Bussink; C. Brink; O. Hansen; P. Lambin |
Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images |
2017 |
|
A. Jochems; T.M. Deist; I.El Naqa; M. Kessler; C. Mayo; J. Reeves; S. Jolly; M. Matuszak; R.Ten Haken; J. van Soest; C. Oberije; C. Faivre-Finn; G. Price; D. De Ruysscher; P. Lambin; A. Dekker |
Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries |
2017 |
|
R.T.H.M. Larue; L. Van De Voorde; J.E. van Timmeren; R.T.H. Leijenaar; M. Berbee; M.N. Sosef; W.M.J. Schreurs; W. van Elmpt; P. Lambin |
Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers |
2017 |
|
S. Carvalho; E.G.C. Troost; J. Bons; P. Menheere; P. Lambin; C. Oberije |
Data from: Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – a survival model with external validation |
2016 |
|
D. Eekers; E. Roelofs; U. Jelen; M. Kirk; M. Granzier; F. Ammazzalorso; P.H. Ahn; G.O.R.J. Janssens; F. Hoebers; T. Friedmann; T. Solberg; S. Walsh; E.G.C. Troost; J.H.A.M. Kaanders; P. Lambin |
Data from: Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicenter in silico ROCOCO trial |
2016 |
|
B. Reymen; M.W. van Gisbergen; A.J.G. Even; C.M.L. Zegers; C. Oberije; F. Mottaghy; M. Das; A. Yaromina; W. van Elmpt; D. De Ruysscher; L. Dubois; P. Lambin |
Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial. |
2016 |
|
P. Lambin |
Radiomics Digital Phantom |
2016 |
|
A. Even; O. Hamming-Vrieze; W. van Elmpt; V. Winnepenninckx; J. Heukelom; M. Tesselaar; W. Vogel; A. Hoeben; C.M.L. Zegers; D. Vugts; G. Van Dongen; H. Bartelink; F. Mottaghy; F. Hoebers; P. Lambin |
Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach |
2016 |
|
Q. Cheng; E. Roelofs; B. Ramaekers; D. Eekers; J. van Soest; T. Lustberg; F. Hoebers; H.Paul van der Laan; E. Korevaar; A. Dekker; J. Langendijk; P. Lambin |
Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness |
2015 |
|
K. Panth; T. van den Beucken; R. Biemans; N. Lieuwes; M. Weber; M. Losen; A. Yaromina; L. Dubois; P. Lambin |
Data from: MMP2 small immuno protein antibody uptake in xenograft tumors is associated with MMP2 activity |
2015 |
|
S. Walsh; E. Roelofs; P. Kuess; P. Lambin; B. Jones; D. Georg; F. Verhaegen |
Data from: A validated Tumor Control Probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy |
2015 |